STSA NASDAQ
Satsuma Pharmaceuticals, Inc.
1W: +4.8%
1M: +1.9%
3M: +24.0%
1Y: -67.7%
3Y: -95.9%
$1.10
Last traded 2023-06-07 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$36.5M
52W Range0.59-8.08
Volume1,826,389
Avg Volume1,210,626
Beta0.10
Dividend—
Analyst Ratings
Company Info
CEOJohn A. Kollins MBA
Employees25
SectorHealthcare
IndustryBiotechnology
IPO Date2019-09-13
Websitesatsumarx.com
400 Oyster Point Boulevard
South San Francisco, CA 94080
US
South San Francisco, CA 94080
US
650 410 3200
About Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMEN | D-Return | 30,000 | $3.46 | 2023-06-08 |
| RA CAPITAL MANAGEMEN | D-Return | 20,000 | $4.60 | 2023-06-08 |
| RA CAPITAL MANAGEMEN | U-Tender | 5,914,252 | $0.91 | 2023-06-08 |
| RA CAPITAL MANAGEMEN | D-Return | 10,000 | $26.99 | 2023-06-08 |
| O'Neil Thomas P. | D-Return | 80,000 | $4.60 | 2023-06-08 |